Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

Simple item page
dc.contributor.authorHájek, Roman
dc.contributor.authorMinařík, Jiří
dc.contributor.authorStraub, Jan
dc.contributor.authorPour, Luděk
dc.contributor.authorJungova, Alexandra
dc.contributor.authorBerdeja, Jesus G.
dc.contributor.authorBoccadoro, Mario
dc.contributor.authorBrozova, Lucie
dc.contributor.authorSpencer, Andrew
dc.contributor.authorvan Rhee, Frits
dc.contributor.authorVela-Ojeda, Jorge
dc.contributor.authorThompson, Michael A.
dc.contributor.authorAbonour, Rafat
dc.contributor.authorChari, Ajai
dc.contributor.authorCook, Gordon
dc.contributor.authorCostello, Caitlin L.
dc.contributor.authorDavies, Faith E.
dc.contributor.authorHungria, Vania T. M.
dc.contributor.authorLee, Hans C.
dc.contributor.authorLeleu, Xavier
dc.contributor.authorPuig, Noemi
dc.contributor.authorRifkin, Robert M.
dc.contributor.authorTerpos, Evangelos
dc.contributor.authorUsmani, Saad Z.
dc.contributor.authorWeisel, Katja C.
dc.contributor.authorZonder, Jeffrey A.
dc.contributor.authorBařinová, Magda
dc.contributor.authorKuhn, Matyáš
dc.contributor.authorŠilar, Jiří
dc.contributor.authorČápková, Lenka
dc.contributor.authorGalvez, Kenny
dc.contributor.authorLu, Jin
dc.contributor.authorElliott, Jennifer
dc.contributor.authorStull, Dawn Marie
dc.contributor.authorRen, Kaili
dc.contributor.authorMaisnar, Vladimír
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-07-23T14:22:03Z
dc.date.available2024-07-23T14:22:03Z
dc.date.issued2021
dc.description.abstractAim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.
dc.eprint.versionFinal published version
dc.identifier.citationHájek R, Minařík J, Straub J, et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021;17(19):2499-2512. doi:10.2217/fon-2020-1225
dc.identifier.urihttps://hdl.handle.net/1805/42379
dc.language.isoen_US
dc.publisherTaylor & Francis
dc.relation.isversionof10.2217/fon-2020-1225
dc.relation.journalFuture Oncology
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourcePublisher
dc.subjectEffectiveness
dc.subjectIxazomib
dc.subjectMultiple myeloma
dc.subjectProteasome inhibitor
dc.subjectRelapsed/refractory
dc.subjectRoutine clinical practice
dc.titleIxazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hájek2021Ixazomib-CCBYNCND.pdf
Size:
1.99 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works